News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
582,214 Results
Type
Article (20662)
Company Profile (319)
Press Release (561227)
Multimedia
Podcasts (114)
Webinars (15)
Section
Business (194248)
Career Advice (434)
Deals (29853)
Drug Delivery (54)
Drug Development (71228)
Employer Resources (39)
FDA (12239)
Job Trends (10553)
News (284968)
Policy (22150)
Tag
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (3)
2027 Biotech Bay Elite (4)
2027 Biotech Bay Standard (5)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (5)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (1235)
Accelerated approval (42)
ADA (38)
Adcomms (16)
Allergies (148)
Alliances (41158)
ALS (216)
Alzheimer's disease (1508)
Antibody-drug conjugate (ADC) (533)
Approvals (12833)
Artificial intelligence (583)
ASCO (271)
Autoimmune disease (342)
Automation (36)
Bankruptcy (300)
Best Places to Work (8506)
BIO (65)
Biologics (2)
BIOSECURE Act (6)
Biosimilars (178)
BioSpace Insights (82)
Biotechnology (226)
Bladder cancer (177)
Brain cancer (64)
Breast cancer (689)
Cancer (5573)
Cardiovascular disease (406)
Career advice (374)
Career pathing (14)
CAR-T (329)
CDC (8)
Celiac Disease (1)
Cell therapy (898)
Cervical cancer (43)
Clinical research (63447)
Collaboration (2049)
Commercialization (6)
Company closure (3)
Compensation (1563)
Complete response letters (76)
COVID-19 (1443)
CRISPR (124)
C-suite (1153)
Cystic fibrosis (144)
Data (7960)
Denatured (26)
Depression (164)
Dermatology (95)
Diabetes (500)
Diagnostics (4832)
Digital health (46)
Diversity (6)
Diversity, equity & inclusion (12)
Drug discovery (355)
Drug pricing (59)
Drug shortages (5)
Duchenne muscular dystrophy (325)
Earnings (80667)
Editorial (37)
Employer branding (6)
Employer resources (37)
Events (103235)
Executive appointments (995)
FDA (15778)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (25)
Frontotemporal dementia (35)
Funding (1660)
Gene editing (261)
Generative AI (43)
Gene therapy (726)
GLP-1 (690)
Government (1760)
Grass and pollen (4)
Guidances (335)
Healthcare (12011)
Hematology (147)
HIV (68)
Huntington's disease (62)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (107)
Immunology and inflammation (280)
Immuno-oncology (98)
Indications (206)
Infectious disease (1703)
Inflammatory bowel disease (205)
Inflation Reduction Act (12)
Influenza (94)
Intellectual property (309)
Interviews (58)
IPO (14368)
IRA (13)
Job creations (2422)
Job search strategy (337)
JPM (41)
Kidney cancer (20)
Labor market (36)
Layoffs (307)
Leadership (15)
Legal (5658)
Licensing (12)
Liver cancer (66)
Longevity (31)
Lung cancer (763)
Lymphoma (401)
Machine learning (46)
Management (9)
Manufacturing (840)
Marketing (12)
MASH (187)
Medical affairs (1)
Medical device (9912)
Medtech (10077)
Mergers & acquisitions (16712)
Metabolic disorders (1241)
mRNA (191)
Multiple sclerosis (158)
NASH (14)
Neurodegenerative disease (441)
Neuropsychiatric disorders (102)
Neuroscience (3034)
Neurotech (1)
NextGen: Class of 2026 (4131)
Non-profit (1518)
Now hiring (42)
Obesity (521)
Opinion (153)
Ovarian cancer (225)
Pain (232)
Pancreatic cancer (317)
Parkinson's disease (373)
Partnered (21)
Patents (591)
Patient recruitment (780)
Peanut (55)
People (49575)
Pharmaceutical (50)
Pharmacy benefit managers (13)
Phase 1 (20964)
Phase 2 (28637)
Phase 3 (19440)
Pipeline (9690)
Policy (117)
Postmarket research (1893)
Preclinical (8950)
Press Release (52)
Prostate cancer (293)
Psychedelics (75)
Radiopharmaceuticals (345)
Rare diseases (1118)
Real estate (3776)
Recruiting (14)
Regulatory (19484)
Reports (33)
Research institute (1325)
Resumes & cover letters (60)
Rett syndrome (49)
RNA editing (31)
RSV (57)
Schizophrenia (173)
Series A (309)
Series B (222)
Service/supplier (5)
Sickle cell disease (118)
Special edition (21)
Spinal muscular atrophy (143)
Sponsored (21)
Startups (3116)
State (1)
Stomach cancer (8)
Supply chain (72)
Tariffs (19)
The Weekly (86)
Vaccines (574)
Venture capital (106)
Weight loss (266)
Women's health (103)
Worklife (3)
Date
Today (58)
Last 7 days (323)
Last 30 days (2020)
Last 365 days (25799)
2026 (16782)
2025 (25756)
2024 (30027)
2023 (33979)
2022 (43316)
2021 (45740)
2020 (40894)
2019 (29829)
2018 (22461)
2017 (24179)
2016 (22652)
2015 (28865)
2014 (24873)
2013 (20676)
2012 (22487)
2011 (22747)
2010 (22422)
Location
Africa (337)
Alabama (92)
Alaska (3)
Arizona (341)
Arkansas (14)
Asia (28963)
Australia (4448)
California (13754)
Canada (3746)
China (1331)
Colorado (563)
Connecticut (531)
Delaware (370)
Europe (53948)
Florida (2002)
Georgia (418)
Hawaii (4)
Idaho (47)
Illinois (930)
India (86)
Indiana (441)
Iowa (18)
Japan (543)
Kansas (116)
Kentucky (36)
Louisiana (42)
Maine (37)
Maryland (1453)
Massachusetts (9930)
Michigan (320)
Minnesota (631)
Mississippi (5)
Missouri (96)
Montana (32)
Nebraska (14)
Nevada (133)
New Hampshire (75)
New Jersey (3200)
New Mexico (19)
New York (3384)
North Carolina (1682)
North Dakota (9)
Northern California (7041)
Ohio (344)
Oklahoma (15)
Oregon (35)
Pennsylvania (2680)
Puerto Rico (24)
Rhode Island (37)
South America (526)
South Carolina (77)
South Dakota (1)
Southern California (5479)
Tennessee (148)
Texas (2201)
United States (46493)
Utah (401)
Vermont (1)
Virginia (246)
Washington D.C. (51)
Washington State (1107)
West Virginia (2)
Wisconsin (110)
Wyoming (1)
582,214 Results for "nammi therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma
November 8, 2024
·
2 min read
Press Releases
Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF’s Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM
August 6, 2024
·
4 min read
Press Releases
Stuart Therapeutics, Inc. Appoints David Jakeman as Chief Financial Officer
August 18, 2026
·
3 min read
Biotech Beach
Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Multiple Myeloma
Nammi Therapeutics, Inc. (Nammi), an LA-based immunotherapy company, announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead program, QXL138AM, for the treatment of multiple myeloma.
June 13, 2022
·
2 min read
Biotech Bay
Amgen and Biolabs LA at the Lundquist Institute Announce Nammi Therapeutics to Receive the Third Amgen Golden Ticket
Amgen and BioLabs LA at The Lundquist Institute announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticket in Southern California.
January 6, 2023
·
5 min read
Biotech Beach
Nammi Therapeutics Unveils Two Novel Immunotherapies at AACR Conference
Nammi Therapeutics, Inc. (Nammi), an LA-based immunotherapy company, announces its first two cancer drug candidates, one from each of Nammi’s distinctive drug development platforms, Nammisomes and Masked ImmunoCytokines (MIC).
April 9, 2021
·
2 min read
Press Releases
Definium Therapeutics, Inc. Announces Proposed Public Offering
June 23, 2026
·
6 min read
Policy
Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Pancreatic Cancer
Nammi Therapeutics, Inc., a Los Angeles based immunotherapy company, announced that the US Food and Drug Administration has granted orphan drug designation to its lead program, QXL138AM, for the treatment of Pancreatic Cancer.
June 16, 2022
·
2 min read
Press Releases
Crescita Therapeutics Inc. Announces Closing of Arrangement
June 4, 2026
·
3 min read
Press Releases
Neural Therapeutics Inc. Announces Transition to Semi-Annual Financial Reporting
June 19, 2026
·
5 min read
1 of 58,222
Next
